Revolution Medicines(US:RVMD) Globenewswireยท2025-07-30 20:05Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will report its financial results for Q2 2025 on August 6, 2025, after market close, followed by a webcast to discuss these results and corporate progress [1] Company Overview - Revolution Medicines is developing RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - The current R&D pipeline includes daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), which are in clinical development [3] - The company plans to advance RMC-5127, a RAS(ON) G12V-selective inhibitor, into clinical development next [3] - Additional pipeline opportunities focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C) [3]